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Bleeding is a concern after percutaneous coronary intervention (PCI) and subsequent dual
antiplatelet therapy (DAPT). We herein report the incidence and risk factors for major bleed-
ing in the Norwegian Coronary Stent Trial (NORSTENT).
Materials and methods
NORSTENT was a randomized, double blind, pragmatic trial among patients with acute cor-
onary syndrome or stable coronary disease undergoing PCI during 2008–11. The patients
(N = 9,013) were randomized to receive either a drug-eluting stent or a bare-metal stent,
and were treated with at least nine months of DAPT. The patients were followed for a
median of five years, with Bleeding Academic Research Consortium (BARC) 3–5 major
bleeding as one of the safety endpoints. We estimated cumulative incidence of major bleed-
ing by a competing risks model and risk factors through cause-specific Cox models.
Results
The 12-month cumulative incidence of major bleeding was 2.3%. Independent risk factors
for major bleeding were chronic kidney disease, low bodyweight (< 60 kilograms), diabetes
mellitus, and advanced age (> 80 years). A myocardial infarction (MI) or PCI during follow-
up increased the risk of major bleeding (HR = 1.67, 95% CI 1-29-2.15).
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Conclusions
The 12-month cumulative incidence of major bleeding in NORSTENT was higher than
reported in previous, explanatory trials. This analysis strengthens the role of chronic kidney
disease, advanced age, and low bodyweight as risk factors for major bleeding among
patients receiving DAPT after PCI. The presence of diabetes mellitus or recurrent MI among
patients is furthermore a signal of increased bleeding risk.
Clinical trial registration
Unique identifier NCT00811772; http://www.clinicaltrial.gov.
1 Introduction
Dual antiplatelet therapy (DAPT) is mandatory after percutaneous coronary intervention
(PCI) with stent implantation in order to prevent ischemic events [1]. The optimal duration of
DAPT, however, is debated [2]. The risk of ischemic events must be balanced against the risk
of major bleeding imposed by the antithrombotic therapy. For this purpose, several risk pre-
diction tools based on randomized controlled trials (RCTs) [3,4] or observational studies [5],
have been developed. Of note, recent European guidelines [1] and other guidelines worldwide
[6–8] recommend or suggest the use of standardized risk scores, e.g., the DAPT and PRECI-
SE-DAPT scores, to optimize the duration of DAPT. However, the validity and clinical utility
of such scores have been questioned [9]. Obviously, an assessment of ischemic and bleeding
risk relies on valid data. In brief, observational studies, and in particular registry-based studies,
often have a high external validity but have methodological challenges, such as the lack of vali-
dated endpoints, and confounding. On the other hand, explanatory RCTs often have highly
selected study populations that do not necessarily represent the clinical populations in ques-
tion. Pragmatic RCTs, however, have less strict inclusion and exclusion criteria and produce
study populations that more closely resemble clinical practice, still offering the advantage of
increased validity through adjudicated clinical endpoints.
The aims of the current analysis were: 1) to estimate the incidence of major bleeding and to
identify subgroups with increased bleeding risks among stent naïve patients undergoing PCI
with stent implantation and DAPT, 2) to identify risk factors for major bleeding, including
risks associated with a new or recurrent MI or PCI during follow-up. This was achieved using
data from the Norwegian Coronary Stent Trial (NORSTENT) [10].
2 Materials and methods
2.1 Study population
NORSTENT was a randomized, controlled, open-label, multicenter, pragmatic trial [10]. Eligi-
ble participants were stent naïve patients� 18 years with acute coronary syndrome (i.e., MI or
unstable angina pectoris) or stable coronary artery disease who were candidates for percutane-
ous coronary intervention (PCI) with stent implantation. Patients with contraindications
towards DAPT, or patients on oral anticoagulants were excluded. Patients were recruited
between 2008 and 2011, with a maximum follow-up until December 31, 2014.
The participants were randomized to receive either drug-eluting stent(s) (DES) or bare-
metal stent(s) (BMS). Patients were prescribed DAPT with acetylsalicylic acid (ASA) 75 mg
daily indefinitely and clopidogrel 75 mg daily for at least nine months after the PCI, regardless
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of the stent type. Other cardiovascular drugs, e.g., statins, were given according to contempo-
rary clinical guidelines and practice.
2.2 Endpoint
The endpoint was major bleeding, defined as a Bleeding Academic Research Criteria (BARC)
bleeding of 3, 4, or 5 [11]. This endpoint included overt bleeding plus hemoglobin drop of 3
to< 5 g/dL, overt bleeding plus hemoglobin drop� 5 g/dL, cardiac tamponade, bleeding
requiring surgical intervention, or intravenous vasoactive agents, intracranial or intraocular
bleeding, major bleeding related to coronary artery by-pass surgery, or fatal bleeding. End-
points were collected by means of electronic linkage to the Norwegian Patient Registry with
the use of a unique 11-digit Norwegian national identification number for each patient. The
patient registry includes the codes of The International Classification of Diseases, 10th Revi-
sion (ICD-10), with respect to all the main diagnoses and up to 20 secondary diagnoses and all
procedure codes from all hospitalizations in Norway. A broad search was made to identify any
hospitalization for cardiovascular disease and any hospitalization for suspected bleeding. The
specific search criteria have been published [10]. All outcomes were adjudicated by an end-
point committee based on information in hospital records.
2.3 Statistical analysis
We treated the entire study population as a single cohort, i.e., both study arms were merged.
2.3.1 Definition of variables. Chronic kidney disease was defined as an eGFR < 60 ml/
min/1.73 m2 (CKD-EPI, assuming an all-Caucasian study population). Low bodyweight was
defined as body weight < 60 kilograms, or underweight as a body mass index < 18.5 kg/m2 in
sensitivity analyses. Hypertension, hyperlipidemia, or diabetes mellitus were defined to be
present if the patient received pharmacological treatment for any of these conditions. HbA1C
was also measured in a subgroup of n = 5,267, and diabetes mellitus defined as HbA1C� 6.5%
was also used in sensitivity analyses. Acute coronary syndrome (ACS) was defined as non-
ST-elevation MI, ST-elevation MI, or unstable angina pectoris. The stent length refers to the
total stent length per patient, i.e., a patient could receive several stents in one or multiple
lesions.
2.3.2 Multiple imputation. Among all variables considered (Table 1), the combined pro-
portion of missing observations was 17% with a possible missing at random pattern [12,13].
We therefore used multiple imputation with substantive model compatible fully conditional
specification [14]. We recoded or transformed the variables before the imputation [12,13], e.g.,
chronic kidney disease, and included all variables in our imputation model, and ran 20 impu-
tations. All regressions were thus performed on the imputed datasets (N = 9,013). However,
the available case analyses did not differ substantially. Descriptive statistics are based on the
original data.
2.3.3 Survival analysis. We used a competing risks model with all-cause death as the com-
peting risk, i.e., as fatal bleeding is already included in BARC 5 [11], this refers to non-bleeding
related deaths. The cumulative incidence of major bleeding was estimated by the non-
parametric cumulative incidence function, and we report the cumulative incidence at 30 days,
9 months, 12 months, and at 6 years. We also report the incidence rate per 1,000 person-years.
The associations between the explanatory variables and major bleeding were analyzed by
cause-specific, standard Cox proportional hazard (PH) regression. After inspection of scaled
Schoenfield residuals and graphs in the original dataset and in four of the imputed datasets, we
found strong evidence of violation of the PH assumption for acute coronary syndrome.
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We used the modeling strategy and hierarchical backward elimination for interactions as
outlined by Kleinbaum and Klein [15]. Variables for the regression model were included based
on the literature, biological plausibility, availability and directed acyclic graphs (DAGs). Corre-
lations and unadjusted and adjusted associations informed the DAG for the regression model
(S1 Fig in S1 Appendix). The DAG was created using DAGitty 2.3 (www.dagitty.net) [16]. We
estimated unadjusted and multivariable adjusted HRs for all included variables; there were no
clear indications of multicollinearity. A priori (age x sex, weight x sex) and post hoc (CKD x
diabetes mellitus) interaction terms were assessed by the Wald test.
Table 1. Descriptive statistics of patients at baseline. Original data, i.e., available case analysis.
Variable n (%)
Age < 60 3,438 (38.1)
60–79 5,044 (56.0)
80+ 531 (5.9)
Sex Male 6,757 (75.0)
Low bodyweight (< 60 kg) - 381 (4.3)
Missing 172
Chronic kidney disease - 790 (9.2)
Missing 423
Diabetes mellitus - 1,123 (12.5)
Missing 25
Hypertension - 3,791 (42.4)
Missing 67
Hyperlipidemia - 4,868 (54.8)
Missing 135
Current, daily smoking - 3,147 (38.1)
Missing 758
Prior CABG - 593 (6.6)
Prior stroke - 346 (3.8)
Missing 14
Prior MI - 912 (10.2)
Missing 45
Current ACS - 6,319 (70.2)
Missing 14
Multivessel disease - 3,574 (39.7)
Missing 5
Stent length < 20 mma 4,002 (44.4)
20–40 mm 3,311 (36.7)
� 40 mm 1,700 (18.9)
Stent diameter < 3 mma 2,945 (32.7)
3–4 mm 5,437 (60.3)
� 4 mm 630 (7.0)
Missing 1
Number of stents 1a 5,251 (58.3)
2 2,374 (26.3)
� 3 1,388 (15.4)
ACS: Acute coronary syndrome, CABG: Coronary artery bypass graft, CKD: Chronic kidney disease, MI: Myocardial
infarction.
a 70 patients did not receive a stent after randomization and are included in this group.
https://doi.org/10.1371/journal.pone.0247358.t001
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We assessed the risk of major bleeding among patients suffering a myocardial infarction or
undergoing a repeat revascularization during follow-up. A failure variable was created that
combined spontaneous MI, periprocedural MI, target lesion PCI, or PCI of new lesion in tar-
get vessel or non-target vessel. The MI/PCI survival time was set to the minimum survival
time of those endpoints, i.e., time to the first event. The major bleeding survival time was split
in the case of a MI or PCI, and the resulting time varying indicator variable was included in
Cox PH models.
All analyses were performed in Stata 15.1–16.1. A two-side p value <0.05 was considered
statistically significant. We report 95% confidence intervals, unadjusted for multiple
comparisons.
2.4 Ethics
NORSTENT (ClinicalTrials.gov: NCT00811772) has been approved by the Regional Commit-
tee for Medical and Health Research Ethics (Regional komité for medisinsk og helsefaglig for-
skningsetikk (REK) nord, 40/2008). Participants provided written informed consent. This
substudy is a part of a larger research project, approved by the local Data Protection Officer at
the University Hospital of North Norway.
3 Results
3.1 Baseline characteristics
Baseline characteristics are shown in Table 1. Of the study population, 4509 participants were
randomized to BMS and 4504 participants to DES. The study population was predominantly
male (75%) with an average age of 63 (± 11) years. The average weight was 83 (± 15) kilograms
and average BMI 27 (± 4) kg/m2. Nine percent of patients had chronic kidney disease, defined
solely based on eGFR. The prevalence of pharmacologically treated diabetes mellitus, hyper-
tension, or hyperlipidemia were 12%, 42%, and 55%, respectively. Thirty-eight percent of the
study population were current daily smokers. The indication for the index PCI procedure was
ACS for 70%, stable coronary artery disease for 29%, and a few patients had ischemic heart fail-
ure or hemodynamic instability (0.5%). The majority (58%) had one stent implanted, while
multivessel disease occurred among 40% of the patients at baseline.
3.2 Incidence of major bleeding
In the course of the 42,716 person-years (median time at risk: 4.9 years), 454 events of major
bleeding occurred. The six-year cumulative incidence of major bleeding was 5.4% (Fig 1).
Sixteen percent (n = 74) of the major bleeding cases occurred within the first 30 days after
the index PCI (cumulative incidence at 30 days = 0.8%) (Fig 1); half of those cases occurred
at the index date or the day after (n = 38). The 12-month cumulative incidence was 2.3%
(n = 209).
The incidence rate of major bleeding was 10.6 per 1,000 person-years overall and was high-
est during the first six-month-interval of follow-up, while being more stable after the first year
(Fig 2). The absolute risks, i.e., crude incidence rates, of major bleeding are shown in Table 2
for selected patient sub groups. The highest absolute rates of major bleeding occurred among
patients� 80 years (27.2 per 1,000 person-years), among those with chronic kidney disease
(25.6 per 1,000 person-years), and among patients with low bodyweight (23.7 per 1,000 per-
son-years). The incidence rates of major bleeding among those randomized to BMS or DES
were 10.7 per 1,000 person-years and 10.6 per 1,000 person-years, respectively.
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Fig 1. Cumulative incidence of major bleeding as defined as Bleeding Academic Research Consortium 3–5
according to the non-parametric cumulative incidence function. Vertical lines in the magnified portion highlight
the cumulative incidence at 30 days, 9 months, and 12 months.
https://doi.org/10.1371/journal.pone.0247358.g001
Fig 2. Incidence rate per 1,000 person-years of major bleeding in consecutive 6-month intervals of the follow-up-
period.
https://doi.org/10.1371/journal.pone.0247358.g002
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3.3 Risk factors
3.3.1 Unadjusted associations. The associations of the explanatory variables with major
bleeding are shown in Table 3. In unadjusted Cox PH models, chronic kidney disease, low body-
weight (i.e.,< 60 kg), female sex, diabetes mellitus, hypertension, prior coronary artery bypass
graft, prior stroke, and multivessel disease were statistically significant explanatory variables. Stent
properties (total length, diameter, or quantity) were not clearly associated with increased bleeding
risk. There were no statistically significant differences in bleeding risk among those randomized to
BMS compared to DES for the patient subgroups included in this study (S2 Fig in S1 Appendix).
3.3.2 Multivariable adjusted associations. In the multivariable adjusted regression
model (Table 3), CKD, diabetes mellitus, and low bodyweight were statistically significant risk
factors. There was no statistically significant difference in the bleeding risk between men and
women, although the point estimate suggested a reduced risk among men (HR = 0.82, 95% CI
0.67–1.03 among men). The bleeding risk increased with age, with three times increased risk
among those aged 80 years or older compared to those below 60 years of age.
Having low bodyweight increased the risk of major bleeding by 89% (HR = 1.89, 95% CI
1.32–2.69). Underweight defined as BMI< 18.5 was statistically non-significant but with a
similar point estimate (available case analysis; HR = 1.69, 95% CI 0.75–3.83). Weight showed a
non-linear association with bleeding risk. The interaction tests with age (p = 0.555) or sex
(p = 0.282) were non-significant, although stratification by sex suggested a trend towards an
increase particularly among women (S1 Table in S1 Appendix).
Diabetes mellitus increased the risk of major bleeding by 56% (HR = 1.56, 95%CI 1.22–
2.00). The sensitivity analysis, with diabetes mellitus being defined as HbA1C� 6.5%, showed
a similar point estimate (available case analysis; HR = 1.38, 95% CI 0.96–2.00, n = 4,364,).
Chronic kidney disease increased the risk of major bleeding by 77% (HR = 1.77, 95% CI
1.37–2.29). There was no statistically significant multiplicative interaction between CKD and
diabetes mellitus (post hoc analysis, p = 0.359).
Table 2. Absolute risks of major bleeding in selected patient sub groups (crude incidence rate per 1,000 patient-
years, available case analysis).
Variable Incidence rate (95% CI)
Overall 10.6 (9.7–11.7)
Age 80+ 27.2 (21.1–35.0)
Chronic kidney disease 25.6 (20.8–31.6)
Low bodyweight (< 60 kg) 23.7 (17.3–32.4)
Prior stroke 18.9 (13.2–27.0)
Diabetes mellitus 16.8 (13.6–20.7)
Prior CABG 16.1 (12.0–21.7)
Female sex 14.9 (12.8–17.5)
Stent length� 40 mm 13.0 (10.7–15.7)
Number of stents� 3 12.8 (10.3–15.9)
Multivessel disease 12.7 (11.1–14.5)
Hypertension 12.7 (11.1–14.5)
Stent diameter < 3 mm 12.0 (10.3–14.0)
Prior MI 11.9 (9.0–15.7)
Current ACS 10.6 (9.5–11.8)
Hyperlipidemia 10.4 (9.1–11.8)
ACS: Acute coronary syndrome, CABG: Coronary artery bypass graft, CKD: Chronic kidney disease, MI: Myocardial
infarction.
https://doi.org/10.1371/journal.pone.0247358.t002
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3.3.3 Myocardial infarction or revascularization during follow-up. Patients with MI/
PCI during follow-up were generally older, and more likely to have CKD, diabetes mellitus,
hypertension, hyperlipidemia, previous stroke, CABG, or MI, multivessel disease, as well as
longer total stent length, lower mean stent diameter, and higher number of stents (S2 Table in
Table 3. Hazard ratios for major bleeding in unadjusted and mutually adjusted models. The dataset has been imputed to N = 9,013 by multiple imputation.
Unadjusted Adjusteda
HR 95% CI HR 95% CI
CKD No CKD 1 Ref 1 Ref
CKD 2.65 (2.10–3.35) 1.77 (1.37–2.29)
Hypertension No hypertension 1 Ref 1 Ref
Hypertension 1.39 (1.16–1.67) 1.12 (0.92–1.38)
Diabetes mellitus No diabetes 1 Ref 1 Ref
Diabetes 1.69 (1.33–2.14) 1.56 (1.22–2.00)
CABG No prior CABG 1 Ref 1 Ref
Prior CABG 1.54 (1.12–2.11) 1.25 (0.87–1.79)
Stroke No prior stroke 1 Ref 1 Ref
Prior stroke 1.82 (1.26–2.63) 1.39 (0.95–2.02)
Weight � 60 kg 1 Ref 1 Ref
< 60 kg 2.44 (1.76–3.38) 1.89 (1.32–2.69)
Age < 60 1 Ref 1 Ref
60–79 2.22 (1.76–2.79) 1.97 (1.54–2.52)
80+ 4.60 (3.33–6.35) 3.03 (2.09–4.38)
Sex Female 1 Ref 1 Ref
Male 0.62 (0.51–0.76) 0.82 (0.67–1.03)
Hyperlipidemia No hyperlipidemia 1 Ref 1 Ref
Hyperlipidemia 0.96 (0.80–1.16) 0.85 (0.69–1.06)
Prior MI No prior MI 1 Ref 1 Ref
Prior MI 1.14 (0.85–1.53) 0.88 (0.64–1.21)
Stent length < 20 mm 1 Ref 1 Ref
20–40 mm 0.95 (0.77–1.18) 1.08 (0.82–1.44)
� 40 mm 1.25 (0.99–1.59) 1.51 (0.95–2.40)
Stent diameter < 3 mm 1 Ref 1 Ref
3–4 mm 0.87 (0.71–1.04) 0.96 (0.78–1.18)
� 4 mm 0.70 (0.46–1.06) 0.90 (0.58–1.40)
Number of stents 1 1 Ref 1 Ref
2 0.99 (0.80–1.24) 0.84 (0.60–1.16)
� 3 1.24 (0.97–1.59) 0.79 (0.49–1.27)
Current ACS No ACS - - 1 Ref
ACS �
Multivessel disease No multivessel disease 1 Ref 1 Ref
Multivessel disease 1.34 (1.11–1.61) 1.08 (0.87–1.35)
Current, daily smoking No current smoking 1 Ref 1 Ref
Current smoking 0.89 (0.74–1.09) 1.19 (0.95–1.47)
a Mutually adjusted for all listed variables as well as PCI hospital.
� Violation of PH assumption. Modeled as a time varying covariate in the complete case dataset, t0: HRt0 = 1.43 (95% CI 1.00–2.05), HRinteraction = 0.85 (95% CI 0.74–
0.98), and as a regular variable in the imputation model. ACS: Acute coronary syndrome, CABG: Coronary artery bypass graft, CKD: Chronic kidney disease, MI:
Myocardial infarction.
https://doi.org/10.1371/journal.pone.0247358.t003
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S1 Appendix). The 12-month cumulative incidence among those with MI/PCI during follow-
up was 3.9% compared to 2.3% in those without (Kaplan-Meier estimate). MI/PCI during fol-
low-up increased the risk of major bleeding by 67% (HR = 1.67, 95% CI 1.29–2.15), after
adjustment (S3 Table in S1 Appendix).
3.4 Adherence
Adherence to antiplatelet therapy was assessed through regular interviews, and these results
can be found in the supplement (S4 Table in S1 Appendix).
4 Discussion
4.1 Main findings
In this large, pragmatic randomized trial on PCI with stent implantation and subsequent
DAPT among stent naïve patients, we found a 12-month cumulative incidence of BARC
major bleeding of 2.3%. The presence of chronic kidney disease, diabetes mellitus, low body-
weight, or advanced age increased the risk of major bleeding. A myocardial infarction or a
repeat revascularization during follow-up also increased the risk of major bleeding.
4.2 Incidence of major bleeding
The incidence of major bleeding seems higher than reported in previous RCTs, particularly
explanatory RCTs, which included selected patient populations with lower bleeding risk [17].
Investigators of the SECURITY RCT report a 12-month cumulative incidence of BARC 3 or 5
(i.e., CABG related bleeding excluded) major bleeding after DAPT with clopidogrel of 1.1%
[18]. Other explanatory RCTs report a 12-month cumulative incidence in the range 0.5–1.5%,
with differing bleeding definitions [2,17], while the 12-month cumulative incidence of Throm-
bolysis in Myocardial Infarction (TIMI) major bleeding was around 0.7% (1.3% if minor
bleeding is included) in the derivation cohort for the PRECISE-DAPT score; bleeding events
in the first seven days were excluded [3]. In the DAPT RCT, 2.7% of patients were excluded
before randomization, due to a GUSTO major bleeding during the initial 12 months [19]. In
contrast, in all-comer RCTs, such as PRODIGY and GLOBAL LEADERS, which included
broader patient populations, the 12-month cumulative incidence of BARC 3 or 5 bleeding
were 2.0%, and 1.9%, respectively [17], more similar to our findings.
A lower incidence is reported in some registry-based studies. In a recent registry-based vali-
dation study of the DAPT score, major bleeding occurred among 1.2% during the first 12
months of DAPT with mainly clopidogrel [9]. In the EPICOR registry, among patients with
ACS, the two-year cumulative incidence of bleeding was 3.6%, where half (1.7%) were deemed
clinically significant [20].
A higher incidence has been found in other registry-based studies. The finding of a
12-month cumulative incidence of BARC major bleeding of 2.8% from the PARIS registry [21]
is noteworthy. In Danish registry studies, DAPT with clopidogrel after MI or atrial fibrillation
was associated with a yearly incidence of bleeding of 3.7% [22] or 5.0% [23], respectively.
In summary, the cumulative incidence of major bleeding in NORSTENT is seemingly
higher than in previous explanatory RCTs, more comparable to other all-comers RCTs, and
lower than in some, but not all, registry-based studies. A direct comparison is challenging, par-
ticularly due to varying bleeding definitions. However, the highly selected, explanatory RCTs
include a higher proportion of low-risk patients, while pragmatic RCTs and registry-based
studies might be closer to real-life practice. For example, patients with CKD or uncontrolled
hypertension were excluded from SECURITY [18].
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4.3 Risk factors for major bleeding
We identified chronic kidney disease, diabetes mellitus, low bodyweight, and older age as inde-
pendent risk factors for major bleeding. Stent properties were, as expected, not apparently
associated with the risk of major bleeding. We have previously shown that stent type (DES or
BMS) is not associated with major bleeding [10]. Since the study inclusion period (2008–11),
there has been a reduction in the use of BMS; the rate of use of BMS was below one percent in
2017 in countries like Norway [24, p. 28] or Italy [25]. As the DAPT duration historically was
shorter for BMS, which resulted in a reduced bleeding risk, BMS was preferentially used
among patients with high bleeding risk. However, this trend did not influence the findings in
this study, since the participants had similar (or close to similar) DAPT duration regardless of
stent type. Chronic kidney disease was among the strongest risk factors, both in absolute and
relative terms, for major bleeding. Chronic kidney disease is an established risk factor for
bleeding [17], possibly due to reduced platelet reactivity [26], and creatinine clearance is incor-
porated into several risk prediction tools, e.g., the PRECISE-DAPT score [3].
Diabetes mellitus is a well-established ischemic risk factor, although guidelines state that
the presence of diabetes mellitus should not affect DAPT duration [1]. The potential role of
diabetes mellitus as a risk factor for bleeding is more controversial. In the derivation cohort of
the PRECISE-DAPT score, insulin-dependent diabetes mellitus was associated with a 65%
increased risk of TIMI major or minor bleeding in unadjusted analyses [3]; diabetes mellitus
is, however, not included in the final PRECISE-DAPT score. While in the joint ischemic and
bleeding risk “DAPT score”, diabetes mellitus adds to the ischemic side of the equation [4].
Lemesle et al. recently reported findings from the CORONOR registry of an increased risk
of bleeding in patients with stable coronary artery disease and diabetes mellitus, treated with
aspirin and/or clopidogrel (roughly 40% received clopidogrel; HR = 1.75, 95% CI 1.05–2.91
among diabetic patients with HbA1C level� 7%) [27]. Simek et al., on the contrary, recently
report no association between diabetes mellitus and bleeding in MI patients treated with pra-
sugrel or ticagrelor, based on information from the PRAGUE-18 trial [28]. The authors note
that the bleeding risk among diabetic patients may be differential among users of clopidogrel
and, particularly, prasugrel [28]. The patients included in the CORONOR, NORSTENT, and
the aforementioned derivation cohort of the PRECISE-DAPT score, where an association
between diabetes mellitus and bleeding has been found, mainly received clopidogrel and ASA.
The exact mechanisms whereby diabetes mellitus is associated with bleeding risk is unknown.
Careful interpretation is advisable while we await further data on the association between dia-
betes mellitus, DAPT, and bleeding risk.
Patients weighing less than 60 kg, predominately women, were at increased risk of major
bleeding. In the TRITON-TIMI 38 RCT, a body weight < 60 kg was found to be a risk factor
for serious bleeding in an ACS population (HR = 2.30, 95% CI 1.74–3.05) [29]. One explana-
tion could be the increased systemic availability of ASA or other antithrombotic drugs in
patients with low bodyweight; Rothwell et al. report increased risk of major bleeding only
among ASA users with lower body weight (90-kilogram threshold) [30]. Being underweight
may also act as a proxy variable for frailty. Frailty is associated with increased bleeding risk
after PCI [31], but whether this is causal is controversial [17]. The pre-specified cut-off at< 60
kg was somewhat arbitrarily chosen, but based on literature [29].
Patients who suffered an MI or PCI during follow-up had a 67% increased risk of major
bleeding. Bleeding is a common complication of PCI, while an MI or PCI would normally
result in a new or extended course of DAPT, increasing the risk of bleeding. As the study
period covered the time period of the introduction of prasugrel and ticagrelor in contempo-
rary practice in Norway (~2010) [32], patients with an MI during follow-up would be more
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likely to receive one of those, with a corresponding increased bleeding risk [1]. Finally, as
patients suffering a recurrent MI generally perform worse, and have more comorbidities and
risk factors [33], the finding could, partially, be due to residual confounding.
4.4 Strengths
NORSTENT is a researcher-initiated, pragmatic RCT [34], funded by not-for-profit organiza-
tions, that recruited more than 70% of the eligible population and nearly 50% of all patients
undergoing PCI in Norway during the inclusion period. The study has a long follow-up
period, which was complete for all patients by using mandatory national health registries cov-
ering the entire population, giving insight into the risk of bleeding in the PCI population
beyond the period of DAPT. The bleeding endpoints were clinically adjudicated by a blinded
endpoint committee, increasing the validity. The sample size, as opposed to several of the pre-
vious RCTs [17], allowed detection of smaller effect sizes (e.g., HR� 1.3–1.5).
4.5 Weaknesses
We lacked information on other risk factors, e.g., anemia, low white blood cell count, use of
NSAIDs, and frailty, although age, sex, and weight could to some degree capture the latter
[31]. Furthermore, patients with a contraindication against DAPT, e.g., history of bleeding or
thrombocytopenia, users of anticoagulants, and patients with known cancer were excluded,
leading to a possible underestimation of the bleeding risk compared to contemporary clinical
practice.
Since the patients were prescribed clopidogrel for at least nine months according to the pro-
tocol, and the introduction of prasugrel and ticagrelor happened midway through the study
period, we were unable to compare different P2Y12 inhibitors or durations of DAPT in this
analysis. Finally, current PCI procedural techniques have some important differences from
2008–11, including lower use of glycoprotein IIb/IIIa Inhibitors, and higher frequency of
radial access site, resulting in a lower risk of bleeding [35,36].
5 Conclusion
In this large, pragmatic RCT, among patients randomized to PCI with BMS or DES, the
12-month cumulative incidence of major bleeding was 2.3%. This is twice as high as in previ-
ous explanatory RCTs that included more selected patient populations with lower bleeding
risk. Independent risk factor for major bleeding were chronic kidney disease, diabetes mellitus,
low bodyweight, and older age, while an MI or PCI during follow-up increased the risk of
major bleeding by 67%. Diabetes mellitus is well established as an ischemic risk factor, while
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